| Literature DB >> 10465137 |
Abstract
Bromides are no longer a mainstay of epilepsy therapy because of the significant toxicity associated with their use and the availability of safer agents. However, bromides occasionally find a niche in the treatment of patients with refractory seizures, particularly in pediatrics. When the decision to utilize this therapy is made, the clinician may be frustrated by the lack of concise, current information regarding bromides. This review provides an update on the mechanism of action, efficacy, pharmacokinetics, dose, and adverse effects of bromides.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10465137 DOI: 10.1016/s0887-8994(99)00021-1
Source DB: PubMed Journal: Pediatr Neurol ISSN: 0887-8994 Impact factor: 3.372